Aetherium Bio is developing multi-targeting therapeutics for chronic inflammatory diseases driven by chemokine-mediated immune cell infiltration into tissues. Our proprietary computational platform uniquely integrates physics-based molecular dynamics with deep learning to engineer Fc-fusion peptides that neutralize four to six chemokines simultaneously—solving a challenge that has stymied the field for decades. With functionally validated lead candidates in hand, we are advancing toward proof-of-concept efficacy in neurodegenerative and autoimmune indications including ALS and Lupus Nephritis.